Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
Peter Ulz, Jelena Belic, Ricarda Graf, Martina Auer, Ingrid Lafer, Katja Fischereder, Gerald Webersinke, Karl Pummer, Herbert Augustin, Martin Pichler, Gerald Hoefler, Thomas Bauernhofer, Jochen B Geigl, Ellen Heitzer, Michael R Speicher, Peter Ulz, Jelena Belic, Ricarda Graf, Martina Auer, Ingrid Lafer, Katja Fischereder, Gerald Webersinke, Karl Pummer, Herbert Augustin, Martin Pichler, Gerald Hoefler, Thomas Bauernhofer, Jochen B Geigl, Ellen Heitzer, Michael R Speicher
Abstract
Genomic alterations in metastatic prostate cancer remain incompletely characterized. Here we analyse 493 prostate cancer cases from the TCGA database and perform whole-genome plasma sequencing on 95 plasma samples derived from 43 patients with metastatic prostate cancer. From these samples, we identify established driver aberrations in a cancer-related gene in nearly all cases (97.7%), including driver gene fusions (TMPRSS2:ERG), driver focal deletions (PTEN, RYBP and SHQ1) and driver amplifications (AR and MYC). In serial plasma analyses, we observe changes in focal amplifications in 40% of cases. The mean time interval between new amplifications was 26.4 weeks (range: 5-52 weeks), suggesting that they represent rapid adaptations to selection pressure. An increase in neuron-specific enolase is accompanied by clonal pattern changes in the tumour genome, most consistent with subclonal diversification of the tumour. Our findings suggest a high plasticity of prostate cancer genomes with newly occurring focal amplifications as a driving force in progression.
Figures
References
- Barbieri C. E. & Tomlins S. A. The prostate cancer genome: perspectives and potential. Urol. Oncol. 32, 53.e15–53.e22 (2014).
- Baca S. C. et al.. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).
- Barbieri C. E. et al.. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).
- Berger M. F. et al.. The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011).
- Grasso C. S. et al.. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
- Gundem G. et al.. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).
- Hong M. K. et al.. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).
- Robinson D. et al.. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).
- Taylor B. S. et al.. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
- Heitzer E. et al.. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 5, 30 (2013).
- Mohan S. et al.. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 10, e1004271 (2014).
- Heidary M. et al.. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 16, 421 (2014).
- Heitzer E., Auer M., Ulz P., Geigl J. B. & Speicher M. R. Circulating tumor cells and DNA as liquid biopsies. Genome Med. 5, 73 (2013).
- Heitzer E., Ulz P. & Geigl J. B. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61, 112–123 (2015).
- Mermel C. H. et al.. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
- Robbins C. M. et al.. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 21, 47–55 (2011).
- Tomlins S. A. et al.. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
- Attard G. et al.. Prostate cancer. Lancet 387, 70–82 (2016).
- Romanel A. et al.. Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl. Med. 7, 312re10 (2015).
- Azad A. A. et al.. Androgen receptor gene aberrations in circulating cell-free dna: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 21, 2315–2324 (2015).
- Carreira S. et al.. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
- Shen M. M. & Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967–2000 (2010).
- Visakorpi T. et al.. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401–406 (1995).
- Santarius T., Shipley J., Brewer D., Stratton M. R. & Cooper C. S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10, 59–64 (2010).
- Beroukhim R. et al.. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
- Zack T. I. et al.. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
- Ulz P., Heitzer E. & Speicher M. R. Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nat. Genet. 48, 104–106 (2016).
- Bernard D., Pourtier-Manzanedo A., Gil J. & Beach D. H. Myc confers androgen-independent prostate cancer cell growth. J. Clin. Invest. 112, 1724–1731 (2003).
- Malik R. et al.. Targeting the MLL complex in castration-resistant prostate cancer. Nat. Med. 21, 344–352 (2015).
- Luo J. H. et al.. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44, 1012–1024 (2006).
- Zou X. et al.. Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. J. Biomed. Sci. 16, 33 (2009).
- Schilsky R. L. Implementing personalized cancer care. Nat. Rev. Clin. Oncol. 11, 432–438 (2014).
- Sun Y. et al.. Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J. Androl. 16, 319–324 (2014).
- Beltran H. et al.. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J. Clin. Oncol. 30, e386–e389 (2012).
- Mosquera J. M. et al.. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013).
- Lallous N. et al.. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 17, 10 (2016).
- Bettegowda C. et al.. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
- Dawson S. J. et al.. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199–1209 (2013).
- Forshew T. et al.. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra68 (2012).
- Leary R. J. et al.. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012).
- Murtaza M. et al.. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).
- Aryee M. J. et al.. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 169ra10 (2013).
- Liu W. et al.. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559–565 (2009).
- Rubin M. A., Maher C. A. & Chinnaiyan A. M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 29, 3659–3668 (2011).
- Arora V. K. et al.. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309–1322 (2013).
- Asangani I. A. et al.. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278–282 (2014).
- Manning G., Whyte D. B., Martinez R., Hunter T. & Sudarsanam S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
- Rick F. G., Block N. L. & Schally A. V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther. 6, 391–402 (2013).
- Li H. & Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
- McKenna A. et al.. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
- Wang K., Li M. & Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
- Baslan T. et al.. Genome-wide copy number analysis of single cells. Nat. Protoc. 7, 1024–1041 (2012).
- Lai W., Choudhary V. & Park P. J. CGHweb: a tool for comparing DNA copy number segmentations from multiple algorithms. Bioinformatics 24, 1014–1015 (2008).
- Cazier J. B., Holmes C. C. & Broxholme J. GREVE: Genomic Recurrent Event ViEwer to assist the identification of patterns across individual cancer samples. Bioinformatics 28, 2981–2982 (2012).
- Krzywinski M. et al.. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639–1645 (2009).
- van Bokhoven A. et al.. Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205–225 (2003).
- Hay C. W. & McEwan I. J. The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS ONE 7, e32514 (2012).
Source: PubMed